PROGYNY INC (PGNY)
US74340E1038 - Common Stock
We assign a fundamental rating of 7 out of 10 to PGNY. PGNY was compared to 118 industry peers in the Health Care Providers & Services industry. PGNY gets an excellent profitability rating and is at the same time showing great financial health properties. PGNY is valued quite expensively, but it does show have an excellent growth rating. These ratings would make PGNY suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year PGNY was profitable.
In the past year PGNY had a positive cash flow from operations.
Of the past 5 years PGNY 4 years were profitable.
PGNY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of PGNY (8.20%) is better than 92.31% of its industry peers.
With a decent Return On Equity value of 11.22%, PGNY is doing good in the industry, outperforming 79.49% of the companies in the same industry.
The Return On Invested Capital of PGNY (9.57%) is better than 88.89% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PGNY is in line with the industry average of 8.48%.
The last Return On Invested Capital (9.57%) for PGNY is above the 3 year average (8.61%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.2% | ||
| ROE | 11.22% | ||
| ROIC | 9.57% |
ROA(3y)10.72%
ROA(5y)8.95%
ROE(3y)15.14%
ROE(5y)13.15%
ROIC(3y)8.61%
ROIC(5y)7.94%
1.3 Margins
PGNY's Profit Margin of 5.70% is amongst the best of the industry. PGNY outperforms 85.47% of its industry peers.
In the last couple of years the Profit Margin of PGNY has declined.
PGNY's Operating Margin of 5.71% is fine compared to the rest of the industry. PGNY outperforms 70.09% of its industry peers.
In the last couple of years the Operating Margin of PGNY has grown nicely.
Looking at the Gross Margin, with a value of 21.93%, PGNY is in line with its industry, outperforming 43.59% of the companies in the same industry.
In the last couple of years the Gross Margin of PGNY has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.71% | ||
| PM (TTM) | 5.7% | ||
| GM | 21.93% |
OM growth 3Y28.9%
OM growth 5YN/A
PM growth 3Y-24.95%
PM growth 5YN/A
GM growth 3Y2.58%
GM growth 5Y3.57%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PGNY is creating some value.
PGNY has more shares outstanding than it did 1 year ago.
PGNY has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 11.79 indicates that PGNY is not in any danger for bankruptcy at the moment.
PGNY has a better Altman-Z score (11.79) than 96.58% of its industry peers.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.79 |
ROIC/WACC1.05
WACC9.13%
2.3 Liquidity
A Current Ratio of 3.44 indicates that PGNY has no problem at all paying its short term obligations.
With an excellent Current ratio value of 3.44, PGNY belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
A Quick Ratio of 3.44 indicates that PGNY has no problem at all paying its short term obligations.
PGNY has a Quick ratio of 3.44. This is amongst the best in the industry. PGNY outperforms 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.44 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 106.67% over the past year.
PGNY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 97.89% yearly.
Looking at the last year, PGNY shows a very strong growth in Revenue. The Revenue has grown by 38.35%.
Measured over the past years, PGNY shows a very strong growth in Revenue. The Revenue has been growing by 59.52% on average per year.
EPS 1Y (TTM)106.67%
EPS 3Y97.89%
EPS 5YN/A
EPS growth Q2Q333.33%
Revenue 1Y (TTM)38.35%
Revenue growth 3Y46.69%
Revenue growth 5Y59.52%
Revenue growth Q2Q25.96%
3.2 Future
PGNY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.83% yearly.
PGNY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.46% yearly.
EPS Next Y14.43%
EPS Next 2Y28.01%
EPS Next 3Y25.17%
EPS Next 5Y31.83%
Revenue Next Year18.85%
Revenue Next 2Y19.54%
Revenue Next 3Y18.76%
Revenue Next 5Y18.46%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
PGNY is valuated quite expensively with a Price/Earnings ratio of 53.32.
PGNY's Price/Earnings ratio is in line with the industry average.
PGNY is valuated expensively when we compare the Price/Earnings ratio to 28.11, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 46.60, which means the current valuation is very expensive for PGNY.
PGNY's Price/Forward Earnings ratio is in line with the industry average.
PGNY's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.32 | ||
| Fwd PE | 46.6 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as PGNY.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PGNY indicates a somewhat cheap valuation: PGNY is cheaper than 77.78% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.16 | ||
| EV/EBITDA | 38.29 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PGNY does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of PGNY may justify a higher PE ratio.
PGNY's earnings are expected to grow with 25.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.7
PEG (5Y)N/A
EPS Next 2Y28.01%
EPS Next 3Y25.17%
5. Dividend
5.1 Amount
No dividends for PGNY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROGYNY INC
NASDAQ:PGNY (5/7/2024, 7:16:21 PM)
After market: 33.06 0 (0%)33.06
+0.66 (+2.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.18B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.32 | ||
| Fwd PE | 46.6 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)3.7
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.2% | ||
| ROE | 11.22% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 5.71% | ||
| PM (TTM) | 5.7% | ||
| GM | 21.93% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.44 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)106.67%
EPS 3Y97.89%
EPS 5Y
EPS growth Q2Q
EPS Next Y14.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)38.35%
Revenue growth 3Y46.69%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y